Market Overview

Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies

Share:

Turnstone Obtaining License to Neoantigen Identification Methodology
Developed by the La Jolla Institute

Turnstone Planning to Initiate Phase I/II Clinical Trial Utilizing
Personalized Neoantigen Therapy with Proprietary MG1 Viral Platform in
2019

Turnstone Biologics, a clinical-stage immuno-oncology company developing
the next generation of oncolytic viral therapies, and the La Jolla
Institute for Allergy and Immunology today announced that they have
entered into a collaboration and licensing agreement whereby Turnstone
will utilize La Jolla Institute's proprietary neoantigen identification
methodology to select personalized neoantigens to target with its
proprietary viral technologies for the development of new cancer
immunotherapies.

Under the terms of the agreement, Turnstone will license the neoantigen
identification methods developed by La Jolla Institute professors Dr.
Stephen Schoenberger, Division of Developmental Immunology, and Dr.
Bjoern Peters, Division of Vaccine Discovery, for use in cancer
immunotherapies. Turnstone will fund collaborative research to further
develop antigen identification methods for use in a Phase I/II clinical
trial using its proprietary MG1 viral platform, expected to commence in
2019. Turnstone will also make development and regulatory milestone
payments for therapies that utilize La Jolla Institute's technology.

"Neoantigen-based treatments have the potential to transform cancer
patient care by targeting specific genetic mutations in cancer
malignancies," said Dr. Mike Burgess, MBChB, Ph.D., President of
Research and Development of Turnstone. "Neoantigens identified using the
highly-predictive functional-based approach developed at La Jolla
Institute will be incorporated into our MG1 viral platform to form
powerful immunotherapies. We are excited to be collaborating with the La
Jolla Institute with the goal of developing best-in-class personalized
cancer medicines."

"The field of neoantigens has evolved tremendously, and we are
diligently working to more accurately predict patient-specific cancer
mutations that can be targeted to drive more effective cancer
treatments," says Dr. Stephen Schoenberger. "Turnstone has exciting
proprietory technologies for eliciting strong anti-tumor immune
responses and we are looking forward to capitalizing on their novel
approach to bring personalized neoantigen therapies to patients."

Financial terms of the agreement were not disclosed.

About Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company
developing the next-generation of oncolytic viral immunotherapies for
patients with a broad range of solid tumors. The company's Maraba (MG1)
oncolytic virus platform is the first to combine the tumor-killing
effects of an oncolytic virus with a tumor-targeted T-cell vaccine to
harness an individual's own immune system to attack the tumor, with the
goal of preventing recurrence and delivering a cure. Turnstone is
advancing a robust pipeline of preclinical and clinical programs,
including medicines targeting MAGEA3-expressing tumors, such as
non-small cell lung cancer, and HPV positive tumors, such as cervical
and head and neck cancers, both in Phase I/II clinical trials, and
multiple additional therapies entering the clinic by 2019. In 2017,
Turnstone executed the largest strategic partnership in the oncolytic
virus field with AbbVie, and was named a FierceBiotech "Fierce
15" company. The Company's lead investors include Versant Ventures,
OrbiMed, F-Prime Capital Partners and FACIT. For more information,
please visit http://turnstonebio.com/.

About the La Jolla Institute for Allergy and Immunology

The La Jolla Institute for Allergy and Immunology is dedicated to
understanding the intricacies and power of the immune system so that we
may apply that knowledge to promote human health and prevent a wide
range of diseases. Since its founding in 1988 as an independent,
nonprofit research organization, the Institute has made numerous
advances leading toward its goal: life without disease. For more
information, please visit http://www.lji.org/.

View Comments and Join the Discussion!